COPD

Source: us.rd.yahoo.com --- 5 days ago
HealthDay - SUNDAY, Oct. 5 (HealthDay News) -- For patients suffering from chronic obstructive pulmonary disease (COPD), tiotropium (Spiriva) improves lung function and quality of life but does not significantly slow progression of the disease, a new study finds. ...

Source: au.rd.yahoo.com --- 5 days ago
A new study should allay concerns over a drug taken by 200,000 Australians to relieve the symptoms of a debilitating smoker's disease, say experts. ...

Source: www.moreover.com --- 9 days ago
MedWire News: Influenza vaccination in patients with respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD) may not help prevent symptom exacerbations associated with the virus, Canadian researchers report. ...

Source: www.ncbi.nlm.nih.gov --- 10 days ago
Related Articles Tobramycin Nebulizer Solution in severe COPD patients colonized with Pseudomonas aeruginosa: Effects on bronchial inflammation. Adv Ther. 2008 Sep 27; Authors: Dal Negro R, Micheletto C, Tognella S, Visconti M, Turati C INTRODUCTION: Airway colonization with Pseudomonas aeruginosa is frequent in severe chronic obstructive pulmonary disease (COPD) and may lead to progressive inflammatory damage. Inhaled Tobramycin Nebulizer Solution (TNS; a preservative-free formulation) is an effective therapy in chronic P aeruginosa infection in cystic fibrosis and bronchiectasis. In this study we aimed to investigate the effects of a TNS short course on inflammatory markers in bronchial secretions from multiresistant P aeruginosa-colonized patients with severe COPD. To the authors' knowledge, this is the first study to examine this in cases of severe COPD. METHODS: Thirteen COPD patients (GOLD criteria 3-4; mean age 72.7+/-8 years; mean basal forced expiratory volume in 1 second (FEV1) 34.8%+/-8.1%; mean FEV1/forced vital capacity 0.6+/-0.1) were enrolled. All patients were colonized with P aeruginosa and resistant to oral/intravenous specific antibiotics. Eosinophilic cationic protein (ECP), interleukin-1 beta (IL-1beta), interleukin-8 (IL-8), tumor necrosis factor alfa (TNF-alpha), and cell counts were measured in spontaneous secretions before and after a 2-week TNS course (300 mg twice daily). RESULTS: The TNS course induced a sig ...

Source: www.ncbi.nlm.nih.gov --- 3 days ago
Related Articles COPD and Declining FEV1 -- Time to Divide and Conquer? N Engl J Med. 2008 Oct 5; Authors: Reilly JJ PMID: 18836214 [PubMed - as supplied by publisher] ...

Source: news.ninemsn.com.au --- 4 days ago
06 Oct 2008 ...

Source: www.prnewswire.com --- 6 days ago
...

Source: www.medicinenet.com --- 3 days ago
Title: Spiriva Safe, Effective for COPD Patients Category: Health News Created: 10/6/2008 2:00:00 AM Last Editorial Review: 10/6/2008 ...

Source: www.medicinenet.com --- 7 days ago
Title: Beta Blockers May Cut Mortality in COPD Patients After Surgery Category: Health News Created: 10/2/2008 2:00:00 AM Last Editorial Review: 10/2/2008 ...

Source: www.drugs.com --- 4 days ago
Results of 5,993 patient study UPLIFT(R) (Understanding Potential Long-term Impacts on Function with Tiotropium) presented today at European BERLIN, Oct. 6 /PRNewswire/ -- Results of the UPLIFT(R) trial, presented today at the European Respiratory... ...

Source: www.medicalnewstoday.com --- 4 days ago
Treatment with the inhaled anticholinergic tiotropium (Spiriva; Boehringer Ingelheim) significantly improves lung function and quality of life and reduces exacerbations and mortality in patients with chronic obstructive pulmonary disease (COPD), according to results from the landmark UPLIFT study reported at the European Respiratory Society annual congress ( 4-8 October 2008; Berlin, Germany). Further results showed no increase in cardiovascular events, confirming the drug's safety. ...

Source: www.drugs.com --- 4 days ago
Dear colleagues, I have recently read in an article in BMJ that Anti cholenergic used for symptom control in COPD increases the chances of... ...

Source: www.medpagetoday.com --- 4 days ago
BERLIN (MedPage Today) -- Once-daily tiotropium (Spiriva) improved lung function and quality of life for patients with chronic obstructive pulmonary disease, researchers reported here. ...

Source: www.medpagetoday.com --- 9 days ago
ROTTERDAM, The Netherlands (MedPage Today) -- Cardioselective beta-blockers appear to be safe and may improve outcomes for chronic obstructive pulmonary disease (COPD) patients undergoing vascular surgery, researchers found. ...

Source: www.medpagetoday.com --- 3 days ago
ROCKVILLE, Md. (MedPage Today) -- The FDA said today than fresh data suggested no increased risk of stroke, compared with placebo, for users of tiotropium bromide (Spiriva). ...

Source: www.healthcentral.com --- 3 days ago
Early data from a 4-year clinical trial show no increased risk of stroke in patients given Pfizer Inc's lung drug Spiriva compared with placebo, the U.S. Food and Drug Administration said on Tuesday. ...

Source: www.southcoasttoday.com --- 3 days ago
DEAR DR. DONOHUE: I haven't read anything about chronic obstructive pulmonary disease, COPD, in your column. Will you do something on cause and treatments? ...

Source: pr-gb.com --- 4 days ago
Results of the UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) trial, showed that SPIRIVA(R) HandiHaler(R) (tiotropium bromide inhalation powder), sustained improvements in lung function for up to 4 years as measured by FEV(1) (p<0.001) versus placebo in Chronic Obstructive Pulmonary Disease (COPD) patients. It did not significantly reduce the accelerated rate of decline in lung function, as measured by FEV(1), which was the primary endpoint of the study. The landmark study, published online today in the New England Journal of Medicine and presented at the European Respiratory Society (ERS) Annual Congress, also reaffirmed the well-established, long-term... ...

Source: pr-gb.com --- 4 days ago
- Results of 5,993 Patient Study UPLIFT (Understanding Potential Long-term Impacts on Function with Tiotropium) Presented Today at European Respiratory Society Annual Congress - Not for U.S. Media Results of the UPLIFT trial, presented today at the European Respiratory Society (ERS) Annual Congress, demonstrated that tiotropium (SPIRIVA) administered to Chronic Obstructive Pulmonary Disease (COPD)patients, showed sustained improvements in lung function for up to 4 years (p<0.001), although it did not alter the rate of decline in lung function. The landmark study also reaffirmed the favourable safety profile of tiotropium.(1)... ...

Source: www.healingwell.com --- 5 days ago
However, treatment does not slow disease progression, researchers say ...